Responses
Regular and young investigator award abstracts
Clinical trials completed
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting
Compose a Response to This Article
Other responses
No responses have been published for this article.
